5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2020

5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2020

Summary

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin. Blockade of 5-HT6 receptors showed to increase glutamatergic and cholinergic neurotransmission in brain, whereas activation enhances GABAergic signaling in a widespread manner. Antagonism of 5-HT6 receptors facilitates dopamine and norepinephrine release in the frontal cortex while stimulation has the opposite effect. 5-HT6 receptor plays an important role in Alzheimer's disease and other forms of dementia and obesity.
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders and Respiratory which include indications Psychiatric Disorders, Alzheimer's Disease, Cognitive Disorders, Schizophrenia, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Bipolar Disorder (Manic Depression), Dementia, Depression, Generalized Anxiety Disorder (GAD), Idiopathic Pulmonary Fibrosis, Major Depressive Disorder, Neurology, Obesity, Parkinson's Disease, Psychosis, Pulmonary Arterial Hypertension and Schizoaffective Disorder.
The latest report 5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2020, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)
  • The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Overview
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Companies Involved in Therapeutics Development
Adamed Sp zoo
Alla Chem LLC
Avineuro Pharmaceuticals Inc
Celon Pharma SA
H. Lundbeck AS
HEC Pharm Co Ltd
Reviva Pharmaceuticals Inc
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Drug Profiles
ADN-1184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-2013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-3662 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-3208 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-3205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-322 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-492 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilaroxazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HEC-30654AcOH - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idalopirdine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pirdinenserin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT6 Receptor for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Dormant Products
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Discontinued Products
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Product Development Milestones
Featured News & Press Releases
Oct 09, 2019: ChemRar Group of Companies announces the successful completion of the second phase of clinical trials of an innovative drug for the treatment of generalized anxiety disorder
Jun 03, 2019: Reviva Pharmaceuticals announces successful completion of pre-IND meeting with FDA on Brilaroxazine for the treatment of idiopathic pulmonary fibrosis
Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Jan 10, 2018: Avineuro Pharmaceuticals Reported Phase Ib Trial Results of AVN-101
Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension
Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)
Sep 22, 2016: Headline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer’s disease
Jul 07, 2016: Idalopirdine granted Fast Track Designation by U.S. Food and Drug Administration (FDA)
May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016
Apr 11, 2016: Lundbeck to Present Data on Idalopirdine at American Academy of Neurology
Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits
Jul 01, 2015: Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist
Dec 14, 2014: AllaChem Completes Phase Ib/IIa Clinical Study with AV4025, an HCV NS5A Inhibitor
Nov 05, 2013: Reviva Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for RP5063
Oct 10, 2013: Lundbeck and Otsuka Initiate Phase III Clinical Trials on Lu AE58054 as a New Add-on Treatment for Alzheimer's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Adamed Sp zoo, H2 2020
Pipeline by Alla Chem LLC, H2 2020
Pipeline by Avineuro Pharmaceuticals Inc, H2 2020
Pipeline by Celon Pharma SA, H2 2020
Pipeline by H. Lundbeck AS, H2 2020
Pipeline by HEC Pharm Co Ltd, H2 2020
Pipeline by Reviva Pharmaceuticals Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Dormant Products, H2 2020 (Contd..3), H2 2020
Discontinued Products, H2 2020
List of Figures
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook